Pharmaceuticals / Pharmaceutical / Medicine / News

Ionis provides update on development program evaluating PCSK9 antisense medicine for the treatment of hypercholesterolemia

Posted on: Sep 23, 2022   |   Posted by: Biotech Mag Top

ION449 met primary endpoint in Phase 2b SOLANO study for patients with hypercholesterolemia ION449 will not advance into Phase 3 development based on pre-specified criteria...

Other Posts from Biotech Mag Top